Immunology/Inflammation
Read More about this categoryShow Less
The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.
Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].
BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].
Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.
Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].
References
[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.
[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.
[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.
[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.
[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.
[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.
[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.
[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.
Research Areas
- 5-Lipoxygenase(17)
- Apoptosis(675)
- Cyclic GMP-AMP Synthase(6)
- TLR(121)
- Papain(1)
- PGDS(1)
- PGE synthase(26)
- SIKs(12)
- IκB/IKK(68)
- AP-1(11)
- KEAP1-Nrf2(56)
- NOD1(1)
- NF-κB(304)
- Interleukin Related(263)
- 15-lipoxygenase(2)
- Others(10)
- Aryl Hydrocarbon Receptor(40)
- CD73(15)
- Complement System(69)
- Galectin(12)
- IFNAR(54)
- NO Synthase(93)
- NOD-like Receptor (NLR)(66)
- STING(118)
- Reactive Oxygen Species(505)
- FKBP(15)
- eNOS(4)
- iNOS(29)
- nNOS(20)
- Glutathione(54)
- Adaptive Immunity(210)
- Allergy(118)
- Arthritis(34)
- Autoimmunity(181)
- Gastric Disease(94)
- Immunosuppressants(38)
- Immunotherapeutics(4)
- Innate Immunity(566)
- Pulmonary Diseases(109)
- Reactive Nitrogen Species(50)
- Specialized Pro-Resolving Mediators(49)
- Reactive Sulfur Species(28)
- BCL6(5)
- CD20(10)
- CD28(3)
- PSMA(12)
- FAP(16)
- Nuclear Factor of activated T Cells (NFAT)(2)
- Glycoprotein VI(2)
- Tim3(3)
- Hapten(1)
- Nectin-4(2)
- DOCK(1)
- MHC(9)
- Transmembrane Glycoprotein(17)
- TREM receptor(9)
- Inflammation or Immune System Disease(2)
- Musculoskeletal and Skin Disease(1)
- Fc Receptor (FcR)(11)
- IKZF Family(4)
- C-type Lectin-like Receptors (CTLRs)(3)
- Asialoglycoprotein Receptor (ASGPR)(3)
- Human leukocyte immunoglobulin (Ig)-like receptors (LILR)(1)
Products Related to Immunology/Inflammation(4435)
- GC909371,2,3,4,7,8,9-HeptachlorodibenzofuranCAS: 55673-89-7Purity: >95.00%
다이옥신과 유사한 다이벤조퓨란류(polychlorinated dibenzofuran)
- GC909381,2,3,4,7,8-HexachlorodibenzofuranCAS: 70648-26-9Purity: >90.00%
다이옥신과 유사한 다이벤조퓨란류(polychlorinated dibenzofuran)
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC90929 | Trofinetide (acetate) | - | >95.00% | |
글리-프로-글루의 유도체 | ||||
| GC90932 | Lipid 14 | 2430034-05-0 | >95.00% | |
이온화 가능한 양성 아미노 지질 | ||||
| GC90934 | 1,2,3,6,7,8-Hexachlorodibenzo-p-dioxin | 57653-85-7 | >98.00% | |
다수의 염화 디벤조디옥신 | ||||
| GC90937 | 1,2,3,4,7,8,9-Heptachlorodibenzofuran | 55673-89-7 | >95.00% | |
다이옥신과 유사한 다이벤조퓨란류(polychlorinated dibenzofuran) | ||||
| GC90938 | 1,2,3,4,7,8-Hexachlorodibenzofuran | 70648-26-9 | >90.00% | |
다이옥신과 유사한 다이벤조퓨란류(polychlorinated dibenzofuran) | ||||
| GC90949 | Adenosine-5'-O-(3-thiotriphosphate) (sodium salt) | 88453-52-5 | >95.00% | |
P2Y11 수용체 작용제 | ||||
| GC90964 | Lipid Catechol | 2930813-52-6 | >95.00% | |
지질 프로드럭 나노어셈블리 형성에 사용되는 지질 | ||||
| GC90982 | STING Agonist D61 | 2850251-27-1 | >95.00% | |
STING 작용제 | ||||
| GC90986 | LHC165 (hydrate) | - | >95.00% | |
TLR7 작용제 | ||||
| GC90987 | C12-SPM | 2055647-81-7 | >95.00% | |
다분자 분기 사슬 리피도이드 | ||||
| GC91022 | SP-A (196-215) (human) (trifluoroacetate salt) | - | >98.00% | |
서파크탄트 단백질 A의 펩타이드 조각 | ||||
| GC91034 | Lipid 16 | - | >95.00% | |
이온화 가능한 양성 아미노 지질 | ||||
| GC91044 | Bactobolamine | 78013-07-7 | >98.00% | |
면역억제제 | ||||
| GC91050 | Bactobolin A (hydrochloride) | 73543-68-7 | >95.00% | |
항생 및 항암 활성을 가진 미생물 대사산물 | ||||
| GC91052 | Plipastatin A1 | 103651-09-8 | >90.00% | |
효소 억제 및 면역억제 활성을 가진 리포펩타이드 | ||||
| GC91059 | LCC-12 (formate) | - | >98.00% | |
구리(II) 켈레이터 및 메트포르민 유도체 | ||||
| GC91083 | Tiopronin-Cysteine Disulfide | 77591-18-5 | >95.00% | |
티오프로닌의 대사산물 | ||||
| GC91093 | MR2938 | 1044870-65-6 | >95.00% | |
AChE 억제제 | ||||
| GC91095 | Lipid AX4 | 2735814-23-8 | >95.00% | |
이온화 가능한 양이온성 지질 | ||||
| GC91096 | S-72 | 2446799-14-8 | >98.00% | |
미세관 폴리머화의 억제제 | ||||
| GC91099 | HUP-55 | - | >98.00% | |
프롤릴 엔도펩타이제 억제제 | ||||
| GC91105 | Palustric Acid | 1945-53-5 | >95.00% | |
다양한 생물학적 활동을 가진 디테르페노이드 | ||||
| GC91135 | 4-(3,4-Difluorobenzo)curcumin | 1170354-22-9 | >95.00% | |
항기생충 및 항암 활성을 가진 반합성 쿠마린 | ||||
| GC91136 | XY-4 | 474329-47-0 | >95.00% | |
PPARγ의 작용작물 | ||||
